Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 2/20 | 0.38 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32659778 | 1.00 | MAPT (0.42) | MAPTPRKD3LMNAKCNH2RET | |
| SCHEMBL23630568 | 0.92 | MAPT (0.49) | MAPTLMNARETADK | |
| SCHEMBL32659760 | 0.92 | MAPT (0.49) | MAPTLMNARETADK | |
| SCHEMBL32659767 | 0.91 | PRKD3 (0.42) | MAPTPRKD3KCNH2RETADK | |
| SCHEMBL23630546 | 0.91 | PRKD3 (0.42) | MAPTPRKD3KCNH2RETADK | |
| SCHEMBL23630580 | 0.91 | LMNA (0.47) | MAPTLMNARETADKADORA3 | |
| SCHEMBL32659747 | 0.91 | LMNA (0.47) | MAPTLMNARETADKADORA3 | |
| SCHEMBL23630557 | 0.89 | PRKD3 (0.41) | MAPTPRKD3LMNAKCNH2RET | |
| SCHEMBL32659756 | 0.89 | PRKD3 (0.41) | MAPTPRKD3LMNAKCNH2RET | |
| SCHEMBL23630548 | 0.88 | PRKD3 (0.41) | MAPTPRKD3LMNAKCNH2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522606-B2 | Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy | UNIVERSITY OF WASHINGTON (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | UNIVERSITY OF WASHINGTON | 2023-04-20 | — | — | US | disclosed |
| WO-2021142170-A1 | MODIFIED PYRROLO- AND PYRAZOLO- PYRIMIDINES FOR PROSTATE CANCER THERAPY | UNIVERSITY OF WASHINGTON (US) | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125057-A1 | Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy | PDK2, PDK1, PC | MAPT 1534/4885PRKD3 355/4885LMNA 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.